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ABSTRACT
One of the most fascinating aspects of the immune system is its dynamism, meant as the ability to change
and readapt according to the organism needs. Following an insult, we assist to the spontaneous
organization of different immune cells which cooperate, locally and at distance, to build up an appropriate
response. Throughout tumor progression, adaptations within the systemic tumor environment, or
macroenvironment, result in the promotion of tumor growth, tumor invasion and metastasis to distal
organs, but also to dramatic changes in the activity and composition of the immune system. In this work,
we show the changes of the B-cell arm of the immune system following tumor progression in the ApcMin/C
model of colorectal cancer. Tumor macroenvironment leads to an increased proportion of total and IL-10-
competent B cells in draining LNs while activates a differentiation route that leads to the expansion of
IgAC lymphocytes in the spleen and peritoneum. Importantly, serum IgA levels were signiﬁcantly higher in
ApcMin/C than Wt mice. The peculiar involvement of IgA response in the adenomatous transformation had
correlates in the gut-mucosal compartment where IgA-positive elements increased from normal mucosa
to areas of low grade dysplasia while decreasing upon overt carcinomatous transformation. Altogether,
our ﬁndings provide a snapshot of the tumor education of B lymphocytes in the ApcMin/C model of
colorectal cancer. Understanding how tumor macroenvironment affects the differentiation, function and
distribution of B lymphocytes is pivotal to the generation of speciﬁc therapies, targeted to switching B
cells to an anti-, rather than pro-, tumoral phenotype.
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Introduction
Colorectal cancer (CRC) is one of the most common malignan-
cies in the world and, despite the signiﬁcant improvements in
screening and treatments, it remains one of the leading causes
of tumor-related mortality.1 As for other types of tumor,
immunotherapy represents a fundamental ﬁeld of study in
CRC research.2 It is now established that the immune system
plays a critical role in the development and progression of this
type of cancer and that a better understanding of the crosstalk
between tumor and immune system is required to overcome
immunosuppression and tumor escape.3,4 Great effort has been
devolved to address this issue in the context of the tumor
microenvironment (TME). However, tumors release factors
and create networks even with distal compartments, leading to
the generation of the so-called tumor macroenvironment5
which should also be considered to understand the crosstalk
between CRC and the immune system, and therefore to admin-
ister effective immunotherapy.
For many immune cell types it is nowadays possible to
deﬁne a precise and speciﬁc role in the context of the direct or
indirect interaction with the tumor, however the same cannot
be said for the B cell arm of the immune system. Indeed, in
recent years the contribution of B lymphocytes to tumor immu-
nology turned out to be complex and debated since both pro-
tumorigenic and anti-tumor effects have been reported.6-8
Rosenblatt’s group demonstrated that T cell-mediated immune
response to primary tumors was stronger in mice genetically
lacking B lymphocytes and that high frequencies of intratu-
moral B cells were associated with increased recruitment and
proliferation of regulatory T cells within the tumor microenvi-
ronment.9-11 Conversely, CD20 emerged as new positive prog-
nostic factor in high-grade serous ovarian cancer.12 These
examples of “Janus” B cells are consequences of the inherent
complexity of the B cell population.
Traditionally B lymphocytes were described as positive regula-
tors of the immune response due to their fundamental role in
humoral immunity and to their capacity to drive T cell activation
through antigen presentation, co-stimulation and cytokine pro-
duction.13 However, this scenario has become more complex and
fascinating following the ﬁnding that B cells could also be sup-
pressive and, nowadays, phenotypically diverse B cell populations
with regulatory functions have been described in diverse
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autoimmune and inﬂammatory settings.14 An increasing number
of inhibitory mechanisms have been attributed to regulatory B
cells (Bregs) although the production of the immunosuppressive
cytokine interleukin (IL)-10 remains the most studied.15
Most of the literature concerning B cells and CRC focuses on
the TME. In patients with CRC, tumor-associated B cells were
shown to be enriched for activated and terminally differentiated
B cells16 and Berntsson and coworkers assessed the prognostic
impact of tumor-inﬁltrating B cells and plasma cells (PCs) in
CRC.17 However, since B cell differentiation is strictly related
to the speciﬁc immunological context, an important aspect that
needs further investigation is the understanding of how tumor
onset and progression affects B cell biology at the level of the
tumor macroenvironment.
Aim of this work was to analyze the tumor-mediated educa-
tion of B lymphocytes, not only locally, but especially at the sys-
temic level, in the ApcMin/Cmodel of CRC. The ApcMin/Cmouse
is characterized by a mutation in the gene adenomatous poly-
posis coli (Apc) and presents a predisposition to multiple intes-
tinal neoplasia (Min), as such it is widely used as a model for
familial adenomatous polyposis (FAP) and for the study of
early-stage intestinal tumorigenesis.18 Our data demonstrate
that the frequency and distribution of both B lymphocytes and
IL-10-competent B cells is differently affected depending on
the speciﬁc anatomic site. Speciﬁcally, the IL-10-competent B
cell population was enlarged in the lymph nodes (LNs) of Apc-
Min/C mice while an opposite result was observed in the spleen
where a shift toward IgA-secreting PCs steals the show. This
study sheds new light on the B cell differentiation processes
that occur in the ApcMin/Cmodel of CRC following tumor onset
and progression, and opens a prospect on the speciﬁc targeting
of B cell subsets for immunological therapies.
Results
Tumor onset in ApcMin/Cmice is associated
with a generalized alteration of B cell proportions
in peripheral lymphoid organs
To understand how the tumor macroenvironment affects B cell
biology we focused on the ApcMin/Cmodel of CRC that, beyond
resembling human FAP, represents a perfect setting for the
analysis of how a developing tumor shapes its environment.19,20
Speciﬁcally, the distribution of B lymphocytes was analyzed in
the spleen, peritoneum, mesenteric and inguinal LNs of 18-
weeks old animals. At this stage, ApcMin/C mice of our colonies
had multiple intestinal adenomas (Fig. 1A), but did not present
signs of exacerbated disease such as severe anemia, rectal pro-
lapse or intestinal occlusion.21 Dual cell staining with an anti-
CD19 mAb and the Live/Dead dye revealed that the frequencies
of viable B cells were similar in inguinal LNs of wild-type (Wt)
and ApcMin/C mice, but signiﬁcantly increased in ApcMin/C
mesenteric LNs, directly draining the tumor site (Figs. 1B and
1C, lower panels). Despite a marked increase in the total num-
ber of splenocytes (Fig. S1A), a signiﬁcant decrease of the per-
centages of viable CD19C cells was detected in the spleen of
ApcMin/C mice compared with the Wt counterpart, and the
same result was observed in the peritoneum (Figs. 1B and 1C,
upper panels).
The Apc tumor suppressor gene plays a key role in the trans-
duction of the Wnt-signaling pathway and it has been demon-
strated that the defective Wnt signaling characterizing ApcMin/C
mice inﬂuences the development and differentiation of several
tissues, including haematopoietic tissues.22,23 To exclude that
the mutation per se might be sufﬁcient to explain the altered B
cell distribution observed in 18-weeks old ApcMin/C mice, the
frequencies of viable CD19C cells were analyzed also in 10-
weeks old mice which present few or no macroscopically visible
adenomas (Fig. S1B) and an almost regular cellularity of the
spleen (Fig. S1C). As shown in Fig. 1C, all organs examined in
ApcMin/C mice at 10 weeks of age did not signiﬁcantly differ in
the percentages of viable B cells compared with the Wt counter-
part, indicating that tumor burden is involved in the decrease of
B cell frequencies in systemic tissues and in the opposite
increase detected in mesenteric draining LNs (dLNs).
In light of these results, we evaluated whether the described
ﬁndings were peculiar of this mutation-induced setting or com-
mon to other consolidated CRC models. To this aim, the per-
centages of viable CD19C cells were compared between healthy
controls and mice bearing colitis-associated CRC induced by
azoxymethane/dextran sodium sulfate (AOM/DSS), and mice
implanted subcutaneously with the CT-26 cell line. Interest-
ingly, although the frequencies of viable B cells were not signiﬁ-
cantly altered in the spleen and peritoneum of both these 2
models (Fig. 1D, upper panels), these percentages were remark-
ably higher in inguinal tumor dLNs than in contralateral non-
draining LNs (ndLNs) in the case of the transplanted CT-26
model, and in mesenteric dLNs, but not in inguinal ndLNs, of
the AOM/DSS setting (Fig. 1D, lower panels).
The ﬁnding that the higher B cell proportion in tumor dLNs is
common to all the 3 models led us to investigate whether this
outcome was the result of an increase in B cell proliferation or of
a preferential homing to this lymphoid tissue. The analysis of the
B cells staining positive for the nuclear antigen Ki-67 showed
that an augmented proliferation rate of this population was not
the explanation of the higher percentage of viable CD19C cells
detected in mesenteric LNs of ApcMin/C versus Wt mice, since no
signiﬁcant differences were observed (Fig. 1E). Moreover, the
percentages of CD19CKi-67C cells in ndLNs and dLNs were sim-
ilar in control and CT-26-bearing mice (Fig. S2A). However, the
comparison of Wt and ApcMin/C mesenteric LNs showed that
tumor-bearing mice had a signiﬁcantly higher expression of
CXCL12 and a trend toward a higher expression of CXCL13,
CCL19, CCL21 and CCL20, which are all involved in the physio-
logic homing of lymphocytes to secondary lymphoid organs
(Fig. 1F). Interestingly, a similar result was obtained when com-
paring ndLNs and dLNs from control and CT-26-bearing mice
(Fig. S2B). These results indicate that the generation of a lymph
node environment that favors B cell recruitment could be the
explanation for the higher percentages of B cells detected in
dLNs of tumor-bearing mice.
Opposite effect of ApcMin/C-induced intestinal
tumorigenesis on the IL-10-competent B cell
population of the spleen and LNs
B cells exerting regulatory suppressive functions through IL-
10 secretion have been described in different models of
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autoimmune disease, chronic inﬂammation and cancer.24
Given the growing importance of this population, we inves-
tigated whether the differentiation of the IL-10-competent B
cell population was affected by tumor progression in the
ApcMin/C mouse. After stimulation with LPS, PMA, ionomy-
cin and monensin (LPIM) for 5 h,25 the percentages of
CD19CIL-10C cells were analyzed among total B lympho-
cytes of the spleen, peritoneum, mesenteric and inguinal
LNs of 18-weeks old ApcMin/C mice, in comparison to the
Wt counterparts. In the peritoneum, the population of IL-
10-competent B cells was unaffected by the microenviron-
ment alterations occurring in the ApcMin/C model. On the
contrary, both splenic and LN IL-10-competent B cells were
particularly sensitive to these changes since the percentages
of CD19CIL-10C cells were respectively decreased and
increased in ApcMin/C vs. Wt mice (Fig. 2A). These differen-
ces reached statistical signiﬁcance and were not observed
when comparing 10-weeks old animals (Fig. 2B), indicating
that the changes in the IL-10-competent B cell population
occur when intestinal tumors are fully developed.
Since the differentiation route that leads to the genera-
tion of IL-10-competent B cells is strictly environment
dependent,26 we compared the CD19CIL-10C population in
control and tumor-bearing mice also in the CT-26 and
AOM/DSS models. Interestingly, this analysis revealed that
the alteration of the IL-10-competent B cell proﬁle in
Figure 1. B lymphocytes are expanded in tumor-draining LNs of ApcMin/C mice. (A) Representative pictures of hematoxylin/eosin-stained intestine sections of 18-weeks
old Wt and ApcMin/C mice (left) and histological scoring of intestinal adenomas (right). Each symbol of the scatter plot depicts individual mice (n D 12) among the Wt and
ApcMin/C groups. (B, D) Percentages of viable B cells were analyzed among leukocytes isolated from the spleen, peritoneum, inguinal and mesenteric LNs. In all conditions,
cells were treated with LPIM for 5 h before staining. A ﬂow cytometric analysis based on the dual staining with an anti-CD19 mAb and the green Live/Dead probe was
performed. (B) B cell frequencies were compared in 18-weeks old Wt and ApcMin/C mice. Dot plots for one representative experiment are shown. The CD19 vs. Live/Dead
plot allows to identify viable B cells (gated) and excludes both non-B cells, which are negative for CD19 staining, and dead cells, that are positively stained with the Live/
Dead probe. (C) B cell frequencies were evaluated in 10- and 18-weeks old animals. Each symbol depicts individual mice among the Wt and ApcMin/C groups (at least n D
5) while horizontal lines indicate the mean value § SEM. (D) B cell frequencies were evaluated in the CT-26, ApcMin/C and AOM/DSS models of CRC. Each symbol depicts
individual mice among the control and tumor-bearing group (at least nD 3). In the CT-26 model, inguinal LNs were analyzed as draining (triangle symbol) and non-drain-
ing (square symbol) the tumor site. Horizontal lines indicate the mean value § SEM. (E) Cells were isolated from mesenteric LNs of 18-weeks old Wt and ApcMin/C mice
and directly underwent the staining procedure for Ki-67 detection. Percentages of Ki-67C cells were calculated among viable CD19C cells. A representative dot plot and
bar graphs reporting the mean values (C SEM) of 3 independent experiments are shown. (F) Relative expression of cxcl12, cxcl13, ccl19, ccl21 and ccl20, normalized to the
housekeeping gene g3pdh, was analyzed in the total cellular population isolated from the mesenteric LNs of Wt and ApcMin/C mice (n D 4). For each chemokine, the Wt
sample with the lowest expression was used as control and set to one. p < 0.05; p < 0.01; p < 0.001; ns: not signiﬁcant.
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tumor-bearing mice was peculiar of the ApcMin/C model.
Indeed, in both the CT-26 and in the AOM/DSS settings
the rates of CD19CIL-10C cells were comparable between
healthy and tumor-bearing mice in all the anatomic com-
partments analyzed (Fig. 2C).
Wt and ApcMin/C B cells are equally competent
in responding to activating stimuli
A recent paper published by Ganti and coworkers reported a
preferential accumulation of transitional 2-marginal zone pre-
cursor (T2-MZP) Bregs in tumor dLNs of mice bearing B16-
F10 melanomas. This result was explained by the authors as a
mechanism put in place by the tumor itself, which signals via
the lymphatic drainage to induce an immunosuppressive envi-
ronment.27 Similarly, the increased frequencies of CD19CIL-
10C cells detected in dLNs of ApcMin/C mice might be inter-
preted as functional to tumor immune escape.
Conversely, the defect in splenic IL-10-competent B cell per-
centages needed further investigation. We ﬁrst considered the
possibility that Wt and ApcMin/C B cells could respond differ-
ently to classical activation stimuli that we and others have pre-
viously demonstrated being involved in B-cell IL-10
competence and production.25,28 B lymphocytes isolated from
the spleen were cultured in medium alone or with agonistic
anti-CD40 mAb, LPS or CpG and analyzed for cell prolifera-
tion and survival. CFSE dilution assay did not show any rele-
vant difference between Wt and ApcMin/C B cells (Fig. 3A).
Similarly, the viability of untreated and stimulated B cells after
48 h of culture was comparable in the 2 conditions as deter-
mined by staining with annexin V and propidium iodide
(Table S1). Stimulation through CD40 is required for the devel-
opment, maturation, and/or expansion of IL-10-competent B
cells while TLR agonists are necessary for the production and
secretion of this cytokine.25,28,29 Interestingly, splenic Wt and
ApcMin/C B cells responded similarly to stimulation in terms of
IL-10 competence and production. Indeed, an average percent-
age of CD19CIL-10C cells of about 5% was detected in both
conditions after 48 h of stimulation with the agonistic anti-
CD40 mAb (Fig. 3B) and the amounts of IL-10 secreted upon
LPS or CpG treatment were signiﬁcantly increased in respect of
untreated B cells, but did not differ among the Wt and ApcMin/
C conditions (Fig. 3C, left panel). In addition to IL-10, the pro-
duction of the regulatory marker latency-associated peptide-1
(LAP-1) was analyzed. Again, a very similar trend in terms of
response to stimulation was observed between the 2 conditions,
although B cells isolated from the spleen of ApcMin/C mice pre-
sented a higher basal release of this cytokine compared with
Wt B cells (Fig. 3C, right panel). Altogether these data demon-
strate that a different response to classical B cell stimuli is not
underlie the lower percentage of IL-10-competent B cells
observed in the spleen of ApcMin/Cmice.
Increasing age and adenoma burden lead to a marked
alteration of the B cell proportions among
the phenotypical subsets of the spleen
We subsequently investigated another possible explanation of
the reduced frequency of splenic IL-10-competent B cells that
implied a different B cell distribution among the functional and
phenotypical compartments of the spleen. Based on the differ-
ential expression of the CD21 and CD23 surface markers,
splenic B lymphocytes can be subdivided into at least 3 main
populations, namely the newly formed (NF), marginal zone
(MZ) and follicular (FO) B cell subsets. Three-color CD19/
Figure 2. Tumor progression leads to discrete alterations of IL-10-competent B cell
homeostasis in the ApcMin/C model of CRC. Percentages of IL-10-competent B cells
were analyzed among leukocytes isolated from the spleen, peritoneum, inguinal
and mesenteric LNs. In all conditions, cells were treated with LPIM for 5 h before
staining with the green Live/Dead probe and the anti-mouse CD19 and anti-mouse
IL-10 mAbs. (A) Dot plots from one representative experiment show frequencies of
IL-10C cells among total viable B cells within the indicated gates in 18-weeks old
Wt and ApcMin/C animals. Dead cells were excluded from the analysis using the
CD19 vs. Live/Dead dot plot (data not shown). (B) The IL-10-competent B cell fre-
quencies were evaluated in 10- and 18-weeks old animals. Each symbol depicts
individual mice among the Wt and ApcMin/C groups (at least n D 5) while horizon-
tal lines indicate the mean value § SEM. (C) The IL-10-competent B cell frequen-
cies were evaluated in the CT-26, ApcMin/C and AOM/DSS models of CRC. Each
symbol depicts individual mice among the control and tumor-bearing group (at
least n D 3). In the CT-26 model, inguinal LNs were analyzed as draining (triangle
symbol) and non-draining (square symbol) the tumor site. Horizontal lines indicate
the mean value§ SEM. p < 0.05; p < 0.01; ns: not signiﬁcant.
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CD21/CD23 ﬂow cytometry analyses of Wt and ApcMin/C sple-
nocytes revealed a completely altered distribution of ApcMin/C
B cells which were present in lower percentages among the FO
and MZ compartments (Fig. 4A). The decrease of B lympho-
cytes with a MZ phenotype was conﬁrmed by the triple immu-
noﬂuorescence staining with Abs against the CD19, CD1d and
CD5 molecules. High expression levels of CD1d is a peculiar
feature of MZ B cells30 and, as shown in Fig. 4B, CD19C cells
with a CD1dhi phenotype were reduced in percentage in Apc-
Min/C compared with Wt mice. Moreover, this second type of
staining evidenced a signiﬁcant reduction also in the percentage
of CD1dCCD5C B10 cells which, together with MZ and
T2-MZP B cells, represent a compelling candidate for the regu-
latory activity of B lymphocytes.31 If on one hand the pheno-
typic analyses of ApcMin/C B lymphocytes evidenced a reduced
percentage of B cells with Breg traits, on the other the CD21/
CD23 staining revealed a statistically signiﬁcant enlargement of
the compartments characterized by low/negative levels of the
CD21 receptor (Fig. 4A). Similarly to what observed for the
IL-10-competent B cell analysis (Fig. 2), the altered B cell distri-
bution among the phenotypic subsets was detected when com-
paring 18- but not 10-weeks old Wt and ApcMin/C mice
(Figs. 4C and S3A) and was not paralleled neither in the AOM/
DSS nor in the CT-26 model of CRC (Figs. S3B and S3C).
Therefore, the described changes are peculiar of the mutation-
induced model of CRC, but tumor onset is required for the
manifestation of the phenotype.
ApcMin/Cmice present traits of a skewing toward IgA-
producing cells
Deepening into the characterization of these ApcMin/C CD21low
cells, we observed phenotypic similarities with a small subset of
CD19CCD45Rlow/¡CD21low lymphocytes that was recently
Figure 3. Wt and ApcMin/C splenic B cells respond similarly to activating stimuli. (A) B cells were puriﬁed from the spleen of Wt and ApcMin/C mice, CFSE labeled and cul-
tured either alone (NST) or in the presence of anti-CD40 mAb (a-CD40), LPS or CpG for 72 h. CFSE proﬁles of B cell proliferation in the different conditions are shown for
one representative experiment while bar graphs indicate mean (C SEM) of the B cell proliferation index from 5 independent experiments. (B) The frequencies of B cells
competent to express cytoplasmic IL-10 following a 5 h stimulation with LPIM were analyzed in puriﬁed Wt and ApcMin/C B cells cultured for 48 h with anti-CD40 mAb.
The condition in which cells received only monensin during the last 5 h of culture was used to correctly discriminate IL-10C from IL-10¡ B cells. Dot plots for one represen-
tative experiment are shown together with the frequencies of IL-10C cells among total CD19C lymphocytes. Bar graphs indicate mean (C SEM) percentages of CD19CIL-
10C cells from 6 independent experiments. (C) B cells were cultured either alone (NST) or in the presence of a-CD40 mAb, LPS or CpG for 48 h. Cell supernatants were col-
lected and IL-10 and LAP-1 levels detected by ELISA. Bar graphs indicate mean (C SEM) concentrations from 6 independent experiments and comparison were performed
against the NST condition. p < 0.05; p < 0.01; p < 0.001; ns: not signiﬁcant.
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described in the spleen of adult mice and that is enriched in
natural PCs spontaneously secreting IgG and IgA.32,33 In fact,
the expression of the surface markers CD45R and CD138
resulted respectively down- and up-modulated on CD21low
compared with FO and MZ cells (Fig. 5A). These phenotypic
similarities raised our interest in understanding whether the
expansion of CD21low B cells was a free-standing event, or
rather the result of a tumor macroenvironment-induced differ-
entiation process aimed at expanding the ﬁnal mediators of the
humoral response.
In this view, we ﬁrst evaluated whether the
CD19CCD45Rlow/¡ population was preferentially found in the
Figure 4. B cells with a CD21low/¡ phenotype are enriched in the spleen of tumor-bearing ApcMin/C mice. Splenocytes were isolated from 18-weeks old Wt and ApcMin/C
mice, stained with anti-CD21, -CD23 and -CD19 (A, C) or with anti-CD1d, -CD5, and -CD19 (B) mAbs and analyzed by ﬂow cytometry. (A, B) Histogram and dot plots show
the analysis of one representative mouse per condition while scatter plots report the mean ( § SEM) percentages of CD19C cells with the phenotype of newly formed
(NF), CD21low, transitional 2-marginal zone precursor (T2-MZP), marginal zone (MZ) and follicular (FO) cells (A) or of CD1dhi, CD1dCCD5¡, CD1dCCD5low and CD1dCCD5C
cells (B). Each symbol depicts individual mice among the Wt and ApcMin/C groups (n D 6 in A; n D 8 in B). (C) The percentages of CD19C cells with a NF, CD21low,
T2-MZP, MZ and FO phenotype were analyzed in 10- and 18-weeks old Wt and ApcMin/C mice (n D 6). p < 0.05; p< 0.01; ns: not signiﬁcant.
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Figure 5. Tumor progression induces a strong IgA response in ApcMin/Cmice. (A) Representative analysis of CD24, CD93, CD45R and CD138 expression on CD21low, FO and
MZ B cells from the spleen of 18-weeks old ApcMin/C mice. Single-color histograms in which cell percentages (y-axis) are plotted against log ﬂuorescence intensity of the
speciﬁc Ag are the result of a 4-color staining. Filled and empty histograms indicate isotype-matched controls and speciﬁc Abs, respectively. For each of the 4 phenotypic
markers in analysis, a plot overlaying the expression patterns among the CD21low, FO and MZ populations is shown on the right. (B) Representative dot plots showing the
CD19CCD45RC and CD19CCD45Rlow/¡ subsets in Wt and ApcMin/C mice. Non-B cells were excluded from the analysis. Bar graphs indicate mean (C SEM) percentages of
CD19CCD45RC and CD19CCD45Rlow/¡ cells among total B lymphocytes from 4 independent experiments. (C) Representative dot plots showing the CD138neg, CD138int
and CD138high subsets in Wt and ApcMin/C mice. Percentages of CD138high cells are also indicated. Non-B cells were excluded from the analysis. Bar graphs indicate mean
(C SEM) percentages of CD138neg, CD138int and CD138hi cells among total B lymphocytes from 6 independent experiments. (D) B cells were cultured either alone (NST)
or in the presence of a-CD40 mAb, LPS or CpG for 48 h. Cell supernatants were collected and IgM, IgG and IgA levels detected by ELISA. Bar graphs indicate mean (C
SEM) concentrations from 4 to 6 independent experiments. (E) Total IgM, IgG and IgA were measured by ELISA in the serum of 18-weeks old Wt and ApcMin/C mice (n D
8). (F) B cells puriﬁed from the peritoneum and spleen of 18-weeks old Wt and ApcMin/C mice were stained for CD45R and IgA and analyzed by ﬂow cytometry. Dot plots
are shown together with the percentages of IgAC cells and are representative of n D 2 (peritoneum) and n D 4 (spleen) experiments. Non-B cells were excluded from
the analysis. The scatter plot reported on the right is the result of the analysis of IgAC cells in the spleen of 10- and 18-weeks old Wt and ApcMin/C mice. (G) Wt and Apc-
Min/C splenocytes were stained for CD19 and CXCR4, CXCR5, CCR6, CCR7, CCR9 or CCR10. The scatter plot reports the mean ﬂuorescence intensity (MFI) of each chemokine
receptor. Each symbol depicts individual mice among the Wt and ApcMin/C groups (at least n D 4) while horizontal lines indicate the mean value § SEM. For CCR10, the
dot plots of one representative experiment are shown with indicated the percentages of CD19CCCR10C cells. p < 0.05; p < 0.01; p < 0.001; ns: not signiﬁcant.
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spleen of our mutation-induced model of CRC and what
we observed was a statistical signiﬁcant increase of
CD19CCD45Rlow/¡ cell percentages in the ApcMin/C compared
with the Wt condition (Fig. 5B). The switch toward a PC phe-
notype in ApcMin/C mice was conﬁrmed by analyzing the
expression of the CD19 and CD138 surface molecules. Several
studies show that the differential expression of these 2 markers
allow to deﬁne distinct intermediate stages of PC differentia-
tion.34 Normal levels of CD19 and intermediate levels of
CD138 (CD138int) characterize the pre-PC population while
high levels of CD138 (CD138high) and a gradual down modula-
tion of CD19 are indicative of a shift to a later stage of differen-
tiation, that is the one of PC.35 Interestingly, the frequency of
CD138high PCs, calculated among total splenic B lymphocytes,
was 2.3-fold higher in ApcMin/C than Wt mice and this differ-
ence reached statistical signiﬁcance (Fig. 5C). Another evidence
strictly associated with the presence of highly differentiated B
cells in the spleen of ApcMin/C mice was obtained by analyzing
immunoglobulin concentrations in culture supernatants of
untreated and in vitro-stimulated B lymphocytes. In fact, in
spite of a comparable release of IgM, both under basal condi-
tions and following activation, ApcMin/C B cells spontaneously
produced signiﬁcantly higher amounts of IgG and IgA com-
pared with Wt B cells (Fig. 5D). Of note, the IgA concentra-
tions detected in the culture medium of untreated ApcMin/C B
cells were 14-fold higher than in Wt B cells and did not reach
comparable levels neither under the effect of in vitro stimula-
tion, revealing a strong in vivo priming of ApcMin/C B cells
toward IgA production. Even more importantly, a comparable
increase in immunoglobulin production and IgA skewing was
not observed when comparing neither 10-weeks old Wt and
ApcMin/C mice (Fig. S4A) nor healthy and CT-26 tumor-bear-
ing mice (Fig. S4B). In this light, we went ahead and assessed
the levels of circulating antibodies. Interestingly, the analysis of
IgM, IgG and IgA abundance in mouse sera revealed that, in
respect to the Wt counterpart, ApcMin/C animals had signiﬁ-
cantly higher concentrations of IgA, but not of IgM and IgG
(Fig. 5E). Again, this difference in IgA titers was not observed
when comparing 10-weeks old mice (Fig. S4C), suggesting the
presence of a correlation between the humoral immune status
and tumor progression.
Altogether these results prompted us to assess whether,
along with the activation of mechanisms responsible for IgA
production, the initiation of this strong IgA response could also
be due to enhanced IgA class switching among the ApcMin/C B
cell pool. The analysis of IgA expression at the cellular level
conﬁrmed this hypothesis since the frequency of B lymphocytes
staining positive for the membrane-bound form of IgA was
higher in ApcMin/C than in control mice, both in the splenic
and peritoneal compartments (Fig. 5F). IgA-secreting PCs
promptly migrate in response to CCL25 and CCL28, 2 chemo-
kines primarily expressed by mucosal epithelial cells.36 Impor-
tantly, when addressing the expression of lymphocyte-
associated chemokine receptors on splenic Wt and ApcMin/C B
cells, we found that CCR10 was the only one to present a statis-
tically signiﬁcant difference in terms of mean ﬂuorescence
intensity (Fig. 5G, left panel). Both the Wt and ApcMin/C B cell
populations were positive for CXCR4, CXCR5, CCR6 and
CCR7 while CCR9 and CCR10 were expressed at lower levels.
However, a higher percentage of CD19CCCR10C cells was
detected among ApcMin/C B lymphocytes (Fig. 5G, right panel),
supporting the evidence of an enrichment in IgA-secreting PCs
in this mutation-induced model of CRC.
B cells produce IgA following co-culture with ApcMin/
C-derived CD11bCGr-1C cells
Our observations showed that developing tumors in
ApcMin/C mice cause a signiﬁcant alteration of splenic B cell
homeostasis, that results in a decreased proportion of
IL-10-competent B cells and in the parallel occurrence of
IgA-secreting cell traits. The alteration of the splenic micro-
environment was not restricted to the B cell compartment
since 18-weeks old, but not 10-weeks old, ApcMin/C mice
presented a signiﬁcantly higher percentage of CD11bCGr-1C
cells, compared with the Wt counterpart (Figs. 6A and
S5A). Although nowadays new biochemical and molecular
characteristics have emerged, historically the co-expression
of the CD11b and Gr-1 markers broadly deﬁnes myeloid-
derived suppressor cells (MDSCs), a heterogeneous popula-
tion of immature granulocytes, macrophages, and dendritic
cells which accumulate in large numbers in lymphoid tis-
sues of tumor-bearing mice.37,38 Since an increasing amount
of data demonstrates an association between the large accu-
mulation of MDSCs and the modulation of B cell differenti-
ation and function in infection, autoimmune and tumor
settings,39-41 we decided to assess whether CD11bCGr-1C
cells took part to the skewing toward IgA-producing cells
observed in ApcMin/C mice.
CD11bCGr-1C cells were isolated from the spleen of 18-
weeks old ApcMin/C mice and cultured with age-matched Wt
CD19C cells at a 1:1 ratio for 48 h, in the presence or absence
of LPS (Fig. 6B). Following co-culture, IgAC B cells were ana-
lyzed by ﬂow cytometry while supernatants were assayed for
IgA and IgG by ELISA. As shown in Fig. 6C, the percentages of
cells staining positive for membrane-bound IgA were not
affected by the presence of CD11bCGr-1C cells, suggesting that
in our experimental system MDSCs do not provide signals
inducing IgA class switching. On the contrary, the interaction
with CD11bCGr-1C cells signiﬁcantly inﬂuenced the produc-
tion of soluble IgA since the concentrations detected among B
cells cultured alone were about 12 times lower than those
detected in the co-culture. When LPS was added to the system,
the release of IgA by B cells alone was higher but still 4 times
lower compared with the condition in which CD11bCGr-1C
cells were also present (Fig. 6D). Strengthening the hypothesis
of a role played by CD11bCGr-1C cells in the enhanced produc-
tion of IgA detected in our mutation-induced model of CRC, is
the result that CD11bCGr-1C cells did not have the same effect
in respect to IgG production. Indeed, as shown in Fig. 6E, LPS
but not MDSCs signiﬁcantly increased the levels of total IgG
released by B lymphocytes. Moreover, a modest increment of
IgG concentrations was detected in the B/MDSC co-culture,
but only in the absence of LPS stimulation. Altogether these
data are suggestive of a relevant role played by CD11bCGr-1C
cells in the in vivo priming received by ApcMin/C B cells, respon-
sible of the increased production of IgA observed in this mouse
model.
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The local distribution of gut IgAC cells is affected
in the adenoma-carcinoma sequence
The colorectal adenoma-carcinoma sequence stands for the
stepwise process that progresses from normal to dysplastic epi-
thelium to carcinoma, and that is associated with the accumula-
tion of multiple clonally selected genetic alterations.42 In light
of the switch of the systemic B lymphocyte population toward
IgA-producing cells, we were ﬁnally interested in investigating
whether also the homeostasis of local mucosal IgAC PCs was
affected by tumor progression and if there was a correlation
between the distribution of IgAC cells and the adenoma-
carcinoma sequence.
Immunohistochemistry was used to examine the IgA-
producing B cell population in the small intestine of Wt and
ApcMin/C mice and revealed the absence of a difference in the
number of IgA-positive elements between the 2 conditions
(Fig. 7A). Nonetheless, the intriguing result of this analysis was
the peculiar distribution of these IgA-positive elements in the
adenoma tissue compared with the normal mucosa of ApcMin/C
mice. In the undamaged mucosa IgAC cells were evenly spread;
however, when moving to the areas affected by the lesion, we
Figure 6. ApcMin/C CD11bCGr-1C cells increase the production of IgA by B lymphocytes. (A) Cells were isolated from the spleen of 18-weeks old Wt and ApcMin/C mice,
stained with anti-CD11b and anti-Gr-1 mAbs and analyzed by ﬂow cytometry. Representative dot plots are reported with indicated the percentages of double positive
cells. The scatter plot shows mean ( § SEM) percentages of CD11bCGr-1C cells among total Wt and ApcMin/C splenocytes of both 10- (n D 4) and 18-weeks old (n D 10)
mice. (B) Gating strategy for purity check of Wt B cells (upper panels) and ApcMin/C CD11bCGr-1C cells (lower panels) in the pre-isolation and post-isolation steps. (C, D, E)
B cells were cultured with CD11bCGr-1C cells for 48 h, in the presence or absence of LPS. After co-culture, cells were stained for CD45R and IgA (C) while culture superna-
tants were assessed by ELISA for the presence of soluble IgA (D) and IgG (E). Dot plots for one representative experiment are shown with indicated the percentages of
IgAC cells among B lymphocytes. Scatter plots indicate mean ( § SEM) percentages of IgAC cells (C) and mean ( § SEM) IgA (D) and IgG (E) concentrations from 4
independent experiments. p < 0.05; p < 0.01; ns: not signiﬁcant.
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clearly observed a high accumulation of IgA-positive elements
close to the areas of low grade dysplasia while these cells were
almost completely extruded from the adenomas (Fig. 7B).
This result prompted the investigation of whether the
observed correlation between the distribution of IgAC cells and
the adenoma-carcinoma sequence had a parallel in the human
setting. In this view, colon biopsy specimens from 10 patients
diagnosed for CRC were analyzed by immunohistochemistry
for the presence and distribution of CD20C, CD138C, IgAC
and IgGC cells in the undamaged mucosa, in areas of low
Figure 7. IgA-positive elements are extruded from intestinal adenocarcinomas both in the mouse and in humans. (A) Quantiﬁcation of IgA-positive elements in small
intestine sections of 10- and 18-weeks old animals. Each symbol depicts individual mice among the Wt and ApcMin/C groups (n D 3) while horizontal lines indicate the
mean value § SEM. Each symbol of the scatter plot is the mean count of 10 ﬁelds (20x). (B) Representative immunohistochemistry analysis of IgA in the small intestine of
18-weeks old ApcMin/C mice. Normal mucosa shows uniform IgA staining while dysplastic regions show a stronger IgA immunoreacticity. Intratumoral IgA-positive ele-
ments were seldomly observed. The comparison of IgA counts within the dysplastic and intratumoral regions are also provided (n D 3). Each symbol of the scatter plot is
the mean count of 10 ﬁelds (20x). (C) Representative immunohistochemistry analysis of anti-CD20, anti-CD138, anti-IgA and anti-IgG immunostaining of formalin-ﬁxed
parafﬁn-embedded intestinal sections of patients affected by CRC. For each human sample, areas of unaffected mucosa, low grade dysplasia and adenocarcinoma were
examined. Counts of CD20C, CD138C, IgAC and IgGC elements are also provided. Each symbol of the scatter plot is the mean count of 5 ﬁelds (40x). Horizontal lines indi-
cate the mean value§ SEM. p < 0.05; p< 0.01; p < 0.001; ns: not signiﬁcant.
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grade-dysplasia and within the adenocarcinoma. Interestingly,
although no major differences were highlighted in the counts
of CD20C and IgGC elements within the lamina propria of nor-
mal mucosa and adenocarcinomas, the density of both CD138C
and IgAC cells showed a peculiar inverted U-shaped trend in
the colorectal adenoma-carcinoma sequence (Fig. 7C). In fact,
anti-IgA and anti-CD138 immunostaining revealed an
increased number of CD138C and IgAC cells in the areas of low
grade dysplasia compared with both unaffected mucosa and
especially to the invasive adenocarcinoma where these elements
were sparsely distributed. Notably, immunoﬂuorescence
microscopy analysis showed the co-localization of the PC
marker CD138 and IgA (Fig. S6). These results are in accor-
dance with previously published studies,43,44 which reported a
reduced density of CD138CIgAC cells in the adenocarcinoma-
associated compared with the undamaged colonic mucosa.
Altogether these results are suggestive of a role of IgAC PCs in
the early phases of CRC progression.
Discussion
In the present study, the crosstalk between B lymphocytes and
tumor was addressed under a novel perspective. Differently
from other works on the topic, our investigation took into anal-
ysis the changes in the distribution, phenotype and functions of
B lymphocytes during tumor progression and was not limited
to the draining LNs and lymphoid structures associated to the
TME. Research in the ﬁeld of tumor immunology is principally
focused on deciphering the immune response toward cancer
and increasing efforts are directed to the study of the intercellu-
lar communication between malignant and non-transformed
cells. This TME-centered point of view detract attention from
an equally important aspect that is the effect on the immune
system of the so-called tumor macroenvironment.45 As
reviewed by Al-Zhoughbi and coworkers, the tumor macroen-
vironment develops as a slow multi-step process, driven by the
release in the blood and/or lymph stream of soluble factors pro-
duced by the tumor and its microenvironment. Cancer is a sys-
temic disease and a better understanding of the role of host
macroenvironment in tumor progression is of clinical
relevance.46
With the aim of studying the systemic interactions between
the tumor and B lymphocytes in the context of CRC, we con-
sidered the ApcMin/C mouse a suitable model due to the possi-
bility of assessing the changes of the B cell population at
different stages of tumor progression. The distribution of B
lymphocytes among different organs, together with the analysis
of classical markers of the splenic B cell phenotype, demon-
strated that the B cell arm of the immune system is signiﬁcantly
affected by tumor progression. The analysis of 10-weeks old
animals showed that the B cell situation in ApcMin/C mice was
almost normal compared with the Wt counterpart. Conversely,
at 18 weeks of age, when the contribution of the tumor macro-
environment is greater, we observed a considerable decrease of
B cell percentages in the spleen, accompanied by a completely
altered B cell phenotypic pattern in the splenic compartment.
The contribution of tumor macroenvironment was also sug-
gested by Cotella and coworkers as possible explanation for
their elegant observation that older, but not younger, ApcMin/C
mice displayed a decrease in pro-, pre- and immature B cells in
the bone marrow.22 Differently from what observed in the
spleen, B lymphocytes were signiﬁcantly increased in percent-
age in mesenteric LNs of 18-weeks old ApcMin/C mice. The
enlargement of the B cell population in tumor draining LNs
was not speciﬁc of the ApcMin/C mouse but, on the contrary, it
appeared to be a generalized mechanism related to tumor onset
since it was observed in 2 other models of CRC set up in this
study and in other recently published reports.27,47 The compar-
ison of the ApcMin/C, CT-26 and AOM/DSS models leads to the
obvious question of why the B cell populations of the spleen
did not act at the same way in the 3 tumor settings. Although
not supported by experimental data, the answer lies in the
diversity inherent to the 3 models. The complexity and speciﬁc
characteristics of the native microenvironment are lost in the
ectopic implantation model, while, in the AOM/DSS setting,
tumors develop under the environmental inﬂuences of chronic
inﬂammation.48 This could also explain the differences
observed when analyzing the percentages of CD19CIL-10C cells
which differed between healthy and tumor-bearing mice in the
ApcMin/C but not in the CT-26 and AOM/DSS models. Indeed,
after a ﬁrst analysis of the B cell population in toto, we focused
on IL-10-competent Bregs that are riding high in the context of
the role of B cells in the TME,49 but have been broadly analyzed
in respect to tumor macroenvironment. Interestingly, as mice
grew older and tumor progression advanced, the percentages of
CD19CIL-10C cells increased in LNs but decreased in the
spleen of ApcMin/Cmice.
If locally the tumor seems to induce an immunosuppressive
environment, systemically several results obtained in this work
lead to speculate a switch to IgA-producing PCs. Fueled by the
curious and unexpected observation that ApcMin/C mice upre-
gulated the CD19CCD45Rlow/¡CD21low population, poised for
spontaneous secretion of IgA and IgG antibodies,32,33 we ana-
lyzed the sera of both Wt and ApcMin/C mice and found that
total IgA, but not IgM and IgG, levels were signiﬁcantly higher
in tumor-bearing compared with healthy mice. This result ﬁnds
support, and becomes even more relevant, in light of the evi-
dence that a relation between elevated serum IgA levels and
cancer had already been brought to light in the 80s in the con-
text of human tumors of the upper respiratory tract and colon50
and, more recently, in neoplastic disorders of breast.51 Our
experiments show that higher percentages of IgA-switched B
cells are present in the spleen and peritoneum of our genetic
model of CRC. In this context, also the greater basal production
of LAP-1 by ApcMin/C B lymphocytes ﬁnds a possible explana-
tion. Indeed, it has been shown that CD40 triggering leads to
IgA switching through induction of endogenous TGF-b and
the unleashing of an autocrine TGF-b-dependent loop.52,53
Moreover, the spontaneous release of large amounts of IgA by
ApcMin/C B cells is suggestive of a strong in vivo, tumor macro-
environment-induced, priming toward IgA production.
Since Wt and ApcMin/C B cells responded very similarly to
the classical activating stimuli, we tested the hypothesis that the
phenotypical and functional changes of the splenic B cell popu-
lation were the consequences of a change in the nature of the
received signals. An increase in the frequency of CD11bCGr-1C
MDSCs was reported to be a trait of tumor progression in sev-
eral mouse tumor models and clinical studies.54 Here we show
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that CD11bCGr-1C cells are expanded in the spleen of our
genetic model of CRC. ApcMin/CMDSCs alone might play a rel-
evant role in the in vivo priming of ApcMin/C B cells toward IgA
production while they might require the cooperation of other
tumor macroenvironment-derived signals to power the differ-
entiation processes leading to the expansion of the ﬁnal media-
tors of the humoral response. These considerations derive from
our in vitro experiments showing that ApcMin/C CD11bCGr-1C
cells are able to induce the production of IgA but not the
expansion of CD138high PCs (data not shown) nor of IgA-
switched B cells. Although the literature regarding the B cell/
MDSC crosstalk is quite diverse and dependent on the speciﬁc
context analyzed, our results are in line with a recently pub-
lished work reporting that, when in vitro cultured with non-
adherent spleen cells, MDSCs promote both proliferation and
differentiation of B cells into IgA-producing PCs.41
The gut mucosa is the site par excellence of IgA-producing
PCs and thus their potential role in tumor progression was ana-
lyzed in the transition from normal to dysplastic epithelium to
carcinoma. The observation that IgA-positive elements were
densely distributed in areas of low grade dysplasia compared
with normal and invasive carcinoma sites, both in the mouse
and in humans, leads to hypothesize that IgAC PCs might play
a role in the initial phases of colonic carcinogenesis, character-
ized by low grade dysplastic lesions, rather than in the overt
stages of malignant transformation in which the cancer exerts
its invasive potential. This result supports a concept now widely
discussed in the literature that is the urgent need to understand
the exact function of IgAC PCs in shaping the immune
response in both the gut and extra-intestinal sites.55,56
In summary, our study shows that the tumor macroenviron-
ment that develops following adenoma burden in the ApcMin/C
model of CRC has a profound effect on the B cell population
also in distal anatomic sites. Deepening our knowledge on this
topic is essential to design speciﬁc therapies, targeted to the
switching of B cells to an anti-, rather than pro-, tumoral
phenotype.
Materials and methods
Animals and cell isolation from mouse tissues
C57BL/6J Wt and C57BL/6J-ApcMin/C mice were purchased
from the Jackson laboratory. Breeding colonies of these animals
were established and maintained under speciﬁc pathogen-free
conditions at the animal facility of the Humanitas Clinical and
Research Center, Milan. 10- and 18-weeks old male ApcMin/C
mice, together with age- and gender-matched Wt littermates,
were used in this study. For the induction of colitis-associated
carcinoma, Wt C57BL/6J mice (8-weeks old) were given a sin-
gle intraperitoneal injection of AOM (Sigma-Aldrich; 10 mg/kg
body weight diluted in saline) and, after 7 days, were subjected
to a 5-day exposure to drinking water containing 2.5% DSS
(MP Biomedicals; MW 36.000–50.000) followed by a 14-day
exposure to normal drinking water. This cycle was repeated
3 times and animals were euthanized at the conclusion of the
treatment course. 9-weeks old female BALB/c mice (Harlan
Laboratories) were maintained in our animal facilities and sub-
cutaneously injected with 2 £ 105 CT-26 tumor cells. CT-26
tumor-bearing mice, and respective controls, were euthanized
within 3 weeks from inoculation.
Single cell suspensions of spleen and LNs were obtained by
mechanical dissociation of organs through 70 mm-pore-size
nylon ﬁlters. Red blood cells in spleen samples were lysed with
ACK lysing buffer (Lonza). Peritoneal cells were obtained
injecting cold PBS supplemented with 3% FBS in the peritoneal
cavity and dislodging any attached cell by massaging the perito-
neum. Facial vein phlebotomy was performed for blood sam-
pling into tubes without additives and serum was obtained
following a 2-step centrifugation method.
All animal experiments were performed in accordance with
the animal care and use committees of the respective institutes.
Adenoma counting and histopathological analysis
Following mouse euthanasia, the intestine was collected, ﬁxed
in formalin and embedded in parafﬁn. Tissue samples were cut
in 4 mm-thick sections, stained with hematoxylin/eosin (Dako)
and analyzed by a blinded pathologist.
Immunohistochemistry and immunoﬂuorescence
Colon biopsy specimens from 10 patients were collected from
the archives of the Human Pathology Section, Department of
Health Science, University of Palermo, and areas of normal
undamaged mucosa, low-grade dysplasia and invasive carci-
noma were analyzed. Samples were ﬁxed in 10% buffered
formalin and parafﬁn embedded. All procedures were in accor-
dance with the Helsinki Declaration. For in situ single-marker
immunohistochemical analysis, 4 mm-thick tissue sections
were deparafﬁnized and rehydrated. Ag unmasking was per-
formed using Novocastra Epitope Retrieval Solutions pH 6 and
pH 9 (Leica Biosystems) in a PT Link pre-treatment module
(Dako) at 98C for 30 min. Sections were then brought to
room temperature (RT) and washed in PBS. After neutraliza-
tion of the endogenous peroxidase with 3% H2O2 and Fc block-
ing by a speciﬁc protein block (Novocastra, Leica Biosystems),
samples were incubated overnight (o/n) at 4C with the follow-
ing primary Abs: mouse monoclonal anti-human CD20 (clone
L26, 1/100 dilution), mouse monoclonal anti-human CD138
(clone MI15, 1/50 dilution), rabbit polyclonal anti-human IgA
(1/200 dilution), mouse monoclonal anti-human IgG (clone
RWP49, 1/200 dilution), all from Leica Biosystems. Staining
was revealed by polymer detection kit (Novocastra, Leica Bio-
systems) and 3,3’-diaminobenzidine tetrahydrochloride (DAB)
substrate-chromogen. Slides were counterstained with Harris
Hematoxylin (Novocastra, Leica Biosystems). Sections were
analyzed under the Axio Scope A1 optical microscope (Zeiss)
and microphotographs were collected through the Axiocam
503 color digital camera (Zeiss) using the Zen2 software. The
quantitative analysis of stained sections was performed by
counting the absolute number of positive cells out of 5 high-
power microscopic ﬁelds (40x).
For the immunohistochemical analysis of IgA in the murine
system, colon sections were deparafﬁnized, hydrated, and sub-
jected to Ag retrieval (EDTA pH 8, 20 min, 98C). After endog-
enous peroxidase block using Peroxidazed 1 (Biocare Medical),
samples were incubated 1 h at RT with the HRP-conjugated
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goat anti-mouse IgA a chain Ab (1:400, Abcam). DAB (Biocare
Medical) was used as a chromogen and slides were counter-
stained with Mayer Emallume (Bio Optica). The quantitative
analysis of stained sections was performed by counting the
absolute number of positive cells out of 10 high-power micro-
scopic ﬁelds (20x).
Cell preparation and B/MDSC co-culture conditions
Mouse CD19 MicroBeads (Miltenyi) were used for the positive
selection of B lymphocytes from total peritoneal cells. The B
cell isolation kit (Miltenyi) was used to isolate B lymphocytes
from total splenocytes. Puriﬁed splenic B cells were cultured at
the ﬁnal concentration of 106 cell/mL, in the presence or
absence of 1 mg/mL anti-mouse CD40 mAb (BD Pharmigen),
10 mg/mL LPS (Sigma-Aldrich) or 5 mg/mL CpG (Sigma-
Aldrich). After 48 h, necrotic and apoptotic cells were detected
by staining with annexin V and propidium iodide (annexin V-
FITC apoptosis detection kit; eBioscience), followed by ﬂow
cytometry analysis. Cell supernatants were collected and the
levels of IL-10 and LAP-1 quantiﬁed by ELISA (eBioscience).
In certain experiments, B cells were labeled by incubation with
5 mmol/L CFSE (Invitrogen-Molecular Probes) for 15 min at
37C and cell proliferation was assessed by ﬂow cytometry after
72 h of culture.
CD11bCGr-1C myeloid cells were isolated using magnetic
cell sorting. Splenocytes were ﬁrst incubated with the anti-Gr-
1-biotin Ab and, after washing, with streptavidin microbeads
(both from Miltenyi). The positive fraction (all CD11bC;
Fig. 6B) was separated by passage through LS MACS columns
(Miltenyi) and used for the co-culture experiments with B lym-
phocytes. The 2 cell types were plated in a 1:1 ratio, in the pres-
ence or absence of 1 mg/mL LPS, which acts as an activatory
signal on both populations.
Immunophenotyping
Single cell suspensions were surface stained using the anti-
mouse mAbs listed in Table S2. Immunoﬂuorescent staining of
IL-10 was performed on leukocytes isolated from spleen, peri-
toneum and LNs and on CD40-activated B lymphocytes. Cells
were resuspended in medium containing 10 mg/mL LPS, 50 ng/
mL PMA (Sigma-Aldrich), 500 ng/mL ionomycin (Sigma-
Aldrich) and 2 mmol/L monensin (eBioscience), and cultured
for 5 h at 37C. IL-10 intracellular staining was performed as
described previously.25 Samples stained for IL-10 also allowed
the evaluation of the percentages of viable B cells among total
leukocytes since a dual staining with the Live/Dead Fixable
Green Dead Cell Stain Probe (Invitrogen-Molecular Probes)
and an anti-CD19 mAb was part of the protocol. For Ki-67
detection, total LN cell suspension was incubated for 15 min at
4C in the dark with the green Live/Dead probe and, sequen-
tially, with the puriﬁed anti-mouse CD16/CD32 mAb (clone
2.4G2; BD Pharmingen). Following CD19 staining, 3 mL of
cold 70% ethanol was added drop by drop to the cell pellet
while vortexing. Samples were incubated at ¡20C for 1 h and,
after 3 washes with PBS, cells were stained with PE anti-mouse
Ki-67 (clone 16A8; BioLegend) following manufacturer’s
instructions.
Stained samples were acquired on FACScan or FACSCalibur
(BD Biosciences) and data were analyzed with FlowJo software
(Tree Star).
RNA isolation and real-time PCR
Total RNA was extracted using EuroGold Trifast reagent
(EuroClone), following manufacturer’s instructions. RNA
(1 mg) was reverse transcribed to cDNA using the Sensi-
FAST cDNA synthesis kit (Bioline). The generated cDNA
was ampliﬁed by quantitative real-time PCR (qPCR) with
the Bio-Rad CFX96 device and using SYBR green as detec-
tion agent (iQTM SYBR Green Super Mix, Bio-Rad). Each
reaction was performed in triplicate and data were collected
and analyzed by the complementary computer software
(CFX Manager software, Bio-Rad). G3PDH transcript levels
were used to normalize samples. Primers used for qPCR
were from Sigma-Aldrich and their sequences are listed in
Table S3.
Quantiﬁcation of secreted IgM, IgG and IgA isotypes
The concentration of IgM, IgG and IgA in cell supernatants or
mouse sera was assessed by ELISA. For the detection of the
IgM isotype, the mouse IgM Ready-SET-Go! kit (eBioscience)
was used. In the case of IgG and IgA a home-made sandwich
ELISA was developed. Brieﬂy, 96-well ﬂat-bottom polystyrene
plates (Corning) were coated with afﬁnity-puriﬁed anti-mouse
IgA (SouthernBiotech) or anti-mouse IgG (Sigma-Aldrich) Abs
at the ﬁnal concentration of 2 mg/mL and 10 mg/mL, respec-
tively. After 1 h incubation at 37C, plates were washed with
0.05% Tween 20 in PBS and blocked with 1% bovine serum
albumin in PBS for 1 h at RT. 100 mL of cell supernatants or of
opportunely diluted mouse sera were added to Ab-coated wells.
Puriﬁed mouse IgA (BD PharMingen) or IgG (Sigma-Aldrich)
were used as standards. After o/n incubation at 4C, plates
were washed and optimal concentration of horseradish peroxi-
dase-conjugated goat anti-mouse IgA (SouthernBiotech;
1:2000) or goat anti-mouse IgG (Pierce; 1:1000) Abs were
added. Next, plates were incubated for 1 h at RT and washed
before the addition of tetramethylbenzidine substrate solution
(Sigma-Aldrich). The reaction was stopped with 2 mol/L sulfu-
ric acid and absorbance was measured at 450 nm.
Statistical analyses
Results are presented as mean § SEM and data analysis was
performed with the Prism GraphPad Software. For compari-
sons between 2 groups the 2-tailed unpaired and paired
Student’s t-tests were used. When multiple comparisons
were necessary, data were analyzed with the one-way
ANOVA test and the Bonferroni correction was used as
post-hoc analysis. In all tests, p values < 0.05 were consid-
ered statistically signiﬁcant.
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